Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A (2018) Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 68:394–424
SEER Cancer Stat Facts: Prostate Cancer. National Cancer Institute. Bethesda, MD, https://seer.cancer.gov/statfacts/html/prost.html
D’Amico AV, Whittington R, Malkowicz SB, Schultz D, Blank K, Broderick GA et al (1998) Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA 280:969–974
Mottet N, Bellmunt J, Bolla M, Briers E, Cumberbatch MG, De Santis M et al (2017) EAU-ESTRO-SIOG guidelines on prostate cancer. Part 1: screening, diagnosis, and local treatment with curative Intent. Eur Urol 71:618–629
Cornford P, Bellmunt J, Bolla M, Briers E, De Santis M, Gross T et al (2017) EAU-ESTRO-SIOG guidelines on prostate cancer. Part II: treatment of relapsing, metastatic, and castration-resistant prostate cancer. Eur Urol 71:630–642
Wallis CJD, Klaassen Z, Bhindi B, Goldberg H, Chandrasekar T, Farrell AM et al (2018) Comparison of abiraterone acetate and docetaxel with androgen deprivation therapy in high-risk and metastatic hormone-naïve prostate cancer: a systematic review and network meta-analysis. Eur Urol 73:834–844
Hofman MS, Emmett L, Sandhu S, Iravani A, Joshua AM, Goh JC et al (2021) [177Lu]Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): a randomised, open-label, phase 2 trial. Lancet 397:797–804
Sartor O, de Bono J, Chi KN, Fizazi K, Herrmann K, Rahbar K et al (2021) Lutetium-177-PSMA-617 for metastatic castration-resistant prostate cancer. N Engl J Med 385(12):1091–1103
Maurer T, Eiber M, Schwaiger M, Gschwend JE (2016) Current use of PSMA-PET in prostate cancer management. Nat Rev Urol 13:226–235
Hope TA, Goodman JZ, Allen IE, Calais J, Fendler WP, Carroll PR (2019) Metaanalysis of 68Ga-PSMA-11 PET accuracy for the detection of prostate cancer validated by histopathology. J Nucl Med 60:786–793
Fanti S, Goffin K, Hadaschik BA, Herrmann K, Maurer T, MacLennan S et al (2021) Consensus statements on PSMA PET/CT response assessment criteria in prostate cancer. Eur J Nucl Med Mol Imaging 48:469–476
Scher HI, Morris MJ, Stadler WM, Higano C, Basch E, Fizazi K et al (2016) Trial design and objectives for castration-resistant prostate cancer: updated recommendations from the prostate cancer clinical trials working group 3. J Clin Oncol 34:1402–1418
IBM Corp. Released 2011. IBM SPSS Statistics for Windows, Version 20.0. Armonk, NY, IBM Corp
Matushita CS, da Silva AMM, Schuck PN, Bardisserotto M, Piant DB, Pereira JL et al (2021) 68Ga-Prostate-specific membrane antigen (psma) positron emission tomography (pet) in prostate cancer: a systematic review and meta-analysis. Int Braz J Urol 47:705–729
Wahl RL, Jacene H, Kasamon Y, Lodge MA (2009) From RECIST to PERCIST: evolving considerations for PET response criteria in solid tumors. J Nucl Med 50:122S-S150
Schmidkonz C, Cordes M, Schmidt D, Bäuerle T, Goetz TI, Beck M, Prante O, Cavallaro A, Uder M, Wullich B, Goebell P, Kuwert T, Ritt P (2018) 68Ga-PSMA-11 PET/CT-derived metabolic parameters for determination of whole-body tumor burden and treatment response in prostate cancer. Eur J Nucl Med Mol Imaging 45:1862–1872
Kuten J, Sarid D, Yossepowitch O, Mabjeesh NJ, Even-Sapir E (2019) [68Ga]Ga-PSMA-11 PET/CT for monitoring response to treatment in metastatic prostate cancer: is there any added value over standard follow-up? EJNMMI Res 9:84
Gupta M, Choudhury PS, Rawal S, Goel HC, Rao SA (2018) Evaluation of RECIST, PERCIST, EORTC, and MDA Criteria for assessing treatment response with Ga68-PSMA PET-CT in metastatic prostate cancer patient with biochemical progression: a comparative study. Nucl Med Mol Imaging 52:420–429
Hope TA, Truillet C, Ehman EC, Afshar-Oromieh A, Aggarwal R, Ryan CJ et al (2017) 68Ga-PSMA-11 PET imaging of response to androgen receptor inhibition: first human experience. J Nucl Med 58:81–84
Vaz S, Hadaschik B, Gabriel M, Herrmann K, Eiber M, Costa D (2020) Influence of androgen deprivation therapy on PSMA expression and PSMA-ligand PET imaging of prostate cancer patients. Eur J Nucl Med Mol Imaging 47:9–15
Paschalis A, Sheehan B, Riisnaes R, Rodrigues DN, Gurel B, Bertan C et al (2019) Prostate-specific membrane antigen heterogeneity and DNA repair defects in prostate cancer. Eur Urol 76:469–478
Emmett L, Yin C, Crumbaker M, Hruby G, Kneebone A, Epstein R et al (2019) Rapid modulation of PSMA expression by androgen deprivation: serial 68Ga-PSMA-11 PET in men with hormone-sensitive and castrate-resistant prostate cancer commencing androgen blockade. J Nucl Med 60:950–954
Murga JD, Moorji SM, Han AQ, Magargal WW, DiPippo VA, Olson WC (2015) Synergistic co-targeting of prostate-specific membrane antigen and androgen receptor in prostate cancer. Prostate 75:242–254
Aggarwal R, Wei X, Kim W, Small EJ, Ryan CJ, Carroll P et al (2018) Heterogeneous flare in prostate-specific membrane antigen positron emission tomography tracer uptake with initiation of androgen pathway blockade in metastatic prostate cancer. Eur Urol Oncol 1:78–82
Leitsmann C, Thelen P, Schmid M, Meller J, Sahlmann CO, Meller B et al (2019) Enhancing PSMA-uptake with androgen deprivation therapy – a new way to detect prostate cancer metastases? Int Braz J Urol 45:459–467
Afshar-Oromieh A, Debus N, Uhrig M, Hope TA, Evans MJ, Holland-Letz T et al (2018) Impact of long-term androgen deprivation therapy on PSMA ligand PET/CT in patients with castration-sensitive prostate cancer. Eur J Nucl Med Mol Imaging 45:2045–2054
Zacho HD, Petersen LJ (2018) Bone flare to androgen deprivation therapy in metastatic, hormone-sensitive prostate cancer on 68Ga-prostate-specific membrane antigen PET/CT. Clin Nucl Med 43:e404–e406
Onal C, Guler OC, Torun N, Reyhan M, Yapar AF (2020) The effect of androgen deprivation therapy on 68Ga-PSMA tracer uptake in non-metastatic prostate cancer patients. Eur J Nucl Med Mol Imaging 47:632–641
Grubmüller B, Rasul S, Baltzer P, Fajkovic H, D’Andrea D, Berndl F, Maj-Hes A, Grubmüller KH, Mitterhauser M, Wadsak W, Pfaff S, Shariat SF, Hacker M et al (2020) Response assessment using [68Ga]Ga-PSMA ligand PET in patients undergoing systemic therapy for metastatic castration-resistant prostate cancer. Prostate 80:74–82
Rights and permissions
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
Disclaimer:
This article is autogenerated using RSS feeds and has not been created or edited by OA JF.
Click here for Source link (https://www.springeropen.com/)
